President, HealthCore
As HealthCore’s co-founder and President, Mark Cziraky, PharmD, has been extensively involved with clinical, health economic and outcomes research for more than 25 years. Prior to becoming President, Mark was most recently responsible for leading Scientific Affairs and global scientific and business development at HealthCore. He has held additional leadership roles at HealthCore including running individual research units and leading business development teams. Mark remains dedicated to HealthCore’s mission to provide information to enable healthcare decision makers to assess the real-world value of pharmaceutical products and medical devices. He serves as a key architect in creating open source research collaborations within the healthcare industry that allow health plans to be involved in research design and execution with various collaborating organizations.
Mark’s experience spans leadership roles in clinical pharmacy practice with a focus on cardiovascular risk management, academics, clinical trial management, health policy, and retrospective and prospective observational research design and conduct. Mark is a nationally recognized presenter on both cardiovascular and health economic and outcomes research related topics and has published numerous original research, review papers, and book chapters in these areas.
Prior to starting HealthCore, Mark held a full-time faculty position at The Philadelphia College of Pharmacy and Science, now part of the University of the Sciences in Philadelphia, and implemented and managed a physician-referred patient care program focused on dyslipidemia management for Blue Cross Blue Shield of Delaware.
As health care costs continue to rise, employers and payers are under increasing cost pressure to optimally manage their members’ care. This White Paper explores the impact of integrated Anthem medical and pharmacy benefits on medical costs.
HealthCore looks forward to the potential, positive impact that real-world evidence may have on regulatory decision making and therapeutics development within the U.S.
We believe pragmatic trials will be a large part of the future of outcomes research – to understanding life science products in real-world settings, evaluating comparative effectiveness and helping to improve patient care.
